No registrations found.
ID
Source
Brief title
Health condition
Fibrin Sealant
CABG surgery
blood transfusion
cost-effectiveness
Sponsors and support
Corporate Staff
Sanquin Blood Bank
Plesmanlaan 1a
2333 BZ Leiden
Phone: 071 568 5060
Joost.vanHilten@sanquin.nl
Sanquin Blood Bank
Intervention
Outcome measures
Primary outcome
Efficacy:
Total amount of blood products used within 48 hrs after surgery
Costs:
Length of ICU stay
Secondary outcome
Efficacy:
- Blood loss
- Reoperation for bleeding
- Wound infection
- Mortality
Costs:
- Length of hospital stay
Study objective
The use of Fibrin Sealant (FS) in CABG surgery will reduce the amount of transfusions required within 48 hrs after surgery as well as the length of ICU stay.
Study design
- First 48 hrs after surgery
- End ICU stay
- Discharge
Intervention
Patients are randomly assigned to receive either FS treatment, up to a maximum of 15 ml FS per patient, or no FS treatment
Department of Cardiothoracic Surgery<br>
PO Box 9600
G. Tavilla
Albinusdreef 2
Leiden 2300 RC
The Netherlands
+31 (0)71 5264022
G.Tavilla@lumc.nl
Department of Cardiothoracic Surgery<br>
PO Box 9600
G. Tavilla
Albinusdreef 2
Leiden 2300 RC
The Netherlands
+31 (0)71 5264022
G.Tavilla@lumc.nl
Inclusion criteria
1. Elective, isolated CABG surgery with the use of at least one internal thoracic artery
2. Age >18 years
Exclusion criteria
1. Exclusive use of venous grafts
2. Any concomitant procedure, including AF ablation
3. Emergency surgery
4. History of bleeding diathesis or coagulopathy
5. Jehova’s witness
6. Participation in any study involving an investigational drug or device
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| NTR-new | NL1326 |
| NTR-old | NTR1386 |
| CCMO | NL21390.058.08 |
| ISRCTN | ISRCTN wordt niet meer aangevraagd |